The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Leukemia Cancer Market Research Report 2024
Synopsis
The global Leukemia Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leukemia Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leukemia Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Leukemia Cancer in Acute Myeloid Leukaemia (AML) is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Leukemia Cancer include Biogen, GSK, Novartis, Pfizer, Roche, Takeda Oncology, Teva Pharmaceutical, Celgene and Daiichi Sankyo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leukemia Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leukemia Cancer.
Report Scope
The Leukemia Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leukemia Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leukemia Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
GSK
Novartis
Pfizer
Roche
Takeda Oncology
Teva Pharmaceutical
Celgene
Daiichi Sankyo
EISAI
Sunesis Pharmaceuticals
Bristol-Myers Squibb
Spectrum Pharmaceuticals
Segment by Type
Chemotherapy
Radiation Therapy
Targeted Therapy
Biological Therapy
Stem Cell Transplant
Segment by Application
Acute Myeloid Leukaemia (AML)
Chronic Myeloid Leukaemia (CML)
Acute Lymphoblastic Leukaemia (ALL)
Chronic Lymphocytic Leukaemia (CLL)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leukemia Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Leukemia Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leukemia Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leukemia Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Leukemia Cancer in Acute Myeloid Leukaemia (AML) is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Leukemia Cancer include Biogen, GSK, Novartis, Pfizer, Roche, Takeda Oncology, Teva Pharmaceutical, Celgene and Daiichi Sankyo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leukemia Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leukemia Cancer.
Report Scope
The Leukemia Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leukemia Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leukemia Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
GSK
Novartis
Pfizer
Roche
Takeda Oncology
Teva Pharmaceutical
Celgene
Daiichi Sankyo
EISAI
Sunesis Pharmaceuticals
Bristol-Myers Squibb
Spectrum Pharmaceuticals
Segment by Type
Chemotherapy
Radiation Therapy
Targeted Therapy
Biological Therapy
Stem Cell Transplant
Segment by Application
Acute Myeloid Leukaemia (AML)
Chronic Myeloid Leukaemia (CML)
Acute Lymphoblastic Leukaemia (ALL)
Chronic Lymphocytic Leukaemia (CLL)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leukemia Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Leukemia Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Radiation Therapy
1.2.4 Targeted Therapy
1.2.5 Biological Therapy
1.2.6 Stem Cell Transplant
1.3 Market by Application
1.3.1 Global Leukemia Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Acute Myeloid Leukaemia (AML)
1.3.3 Chronic Myeloid Leukaemia (CML)
1.3.4 Acute Lymphoblastic Leukaemia (ALL)
1.3.5 Chronic Lymphocytic Leukaemia (CLL)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Leukemia Cancer Market Perspective (2019-2030)
2.2 Leukemia Cancer Growth Trends by Region
2.2.1 Global Leukemia Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Leukemia Cancer Historic Market Size by Region (2019-2024)
2.2.3 Leukemia Cancer Forecasted Market Size by Region (2025-2030)
2.3 Leukemia Cancer Market Dynamics
2.3.1 Leukemia Cancer Industry Trends
2.3.2 Leukemia Cancer Market Drivers
2.3.3 Leukemia Cancer Market Challenges
2.3.4 Leukemia Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Leukemia Cancer Players by Revenue
3.1.1 Global Top Leukemia Cancer Players by Revenue (2019-2024)
3.1.2 Global Leukemia Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Leukemia Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Leukemia Cancer Revenue
3.4 Global Leukemia Cancer Market Concentration Ratio
3.4.1 Global Leukemia Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Leukemia Cancer Revenue in 2023
3.5 Leukemia Cancer Key Players Head office and Area Served
3.6 Key Players Leukemia Cancer Product Solution and Service
3.7 Date of Enter into Leukemia Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Leukemia Cancer Breakdown Data by Type
4.1 Global Leukemia Cancer Historic Market Size by Type (2019-2024)
4.2 Global Leukemia Cancer Forecasted Market Size by Type (2025-2030)
5 Leukemia Cancer Breakdown Data by Application
5.1 Global Leukemia Cancer Historic Market Size by Application (2019-2024)
5.2 Global Leukemia Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Leukemia Cancer Market Size (2019-2030)
6.2 North America Leukemia Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Leukemia Cancer Market Size by Country (2019-2024)
6.4 North America Leukemia Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Leukemia Cancer Market Size (2019-2030)
7.2 Europe Leukemia Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Leukemia Cancer Market Size by Country (2019-2024)
7.4 Europe Leukemia Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Leukemia Cancer Market Size (2019-2030)
8.2 Asia-Pacific Leukemia Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Leukemia Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Leukemia Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Leukemia Cancer Market Size (2019-2030)
9.2 Latin America Leukemia Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Leukemia Cancer Market Size by Country (2019-2024)
9.4 Latin America Leukemia Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Leukemia Cancer Market Size (2019-2030)
10.2 Middle East & Africa Leukemia Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Leukemia Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Leukemia Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Leukemia Cancer Introduction
11.1.4 Biogen Revenue in Leukemia Cancer Business (2019-2024)
11.1.5 Biogen Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Leukemia Cancer Introduction
11.2.4 GSK Revenue in Leukemia Cancer Business (2019-2024)
11.2.5 GSK Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Leukemia Cancer Introduction
11.3.4 Novartis Revenue in Leukemia Cancer Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Leukemia Cancer Introduction
11.4.4 Pfizer Revenue in Leukemia Cancer Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Leukemia Cancer Introduction
11.5.4 Roche Revenue in Leukemia Cancer Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Takeda Oncology
11.6.1 Takeda Oncology Company Detail
11.6.2 Takeda Oncology Business Overview
11.6.3 Takeda Oncology Leukemia Cancer Introduction
11.6.4 Takeda Oncology Revenue in Leukemia Cancer Business (2019-2024)
11.6.5 Takeda Oncology Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Detail
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Leukemia Cancer Introduction
11.7.4 Teva Pharmaceutical Revenue in Leukemia Cancer Business (2019-2024)
11.7.5 Teva Pharmaceutical Recent Development
11.8 Celgene
11.8.1 Celgene Company Detail
11.8.2 Celgene Business Overview
11.8.3 Celgene Leukemia Cancer Introduction
11.8.4 Celgene Revenue in Leukemia Cancer Business (2019-2024)
11.8.5 Celgene Recent Development
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Company Detail
11.9.2 Daiichi Sankyo Business Overview
11.9.3 Daiichi Sankyo Leukemia Cancer Introduction
11.9.4 Daiichi Sankyo Revenue in Leukemia Cancer Business (2019-2024)
11.9.5 Daiichi Sankyo Recent Development
11.10 EISAI
11.10.1 EISAI Company Detail
11.10.2 EISAI Business Overview
11.10.3 EISAI Leukemia Cancer Introduction
11.10.4 EISAI Revenue in Leukemia Cancer Business (2019-2024)
11.10.5 EISAI Recent Development
11.11 Sunesis Pharmaceuticals
11.11.1 Sunesis Pharmaceuticals Company Detail
11.11.2 Sunesis Pharmaceuticals Business Overview
11.11.3 Sunesis Pharmaceuticals Leukemia Cancer Introduction
11.11.4 Sunesis Pharmaceuticals Revenue in Leukemia Cancer Business (2019-2024)
11.11.5 Sunesis Pharmaceuticals Recent Development
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Detail
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Leukemia Cancer Introduction
11.12.4 Bristol-Myers Squibb Revenue in Leukemia Cancer Business (2019-2024)
11.12.5 Bristol-Myers Squibb Recent Development
11.13 Spectrum Pharmaceuticals
11.13.1 Spectrum Pharmaceuticals Company Detail
11.13.2 Spectrum Pharmaceuticals Business Overview
11.13.3 Spectrum Pharmaceuticals Leukemia Cancer Introduction
11.13.4 Spectrum Pharmaceuticals Revenue in Leukemia Cancer Business (2019-2024)
11.13.5 Spectrum Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
